CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从外周血制备兔抗犬 CD19 单克隆抗体及其在免疫检测与 CAR-T 可行性中的验证
英文原题：Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.
查看英文原题
Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
淋巴瘤占犬肿瘤性疾病的24%，占造血系统肿瘤的85%，其中B细胞亚型占60%-80%的病例。作为犬类中最常见的自发性肿瘤，该疾病模型对人类非霍奇金淋巴瘤研究具有重要的转化价值。为解决犬B细胞淋巴瘤的诊断局限性，我们开发了一种高亲和力的犬特异性CD19单克隆抗体（HAC19.1），并建立了兼容流式细胞术和免疫组织化学的双平台检测系统。此外，我们设计了一种新型CD19靶向嵌合抗原受体（CAR）基因序列（HUA-1），并通过慢病毒载体成功转导至Jurkat细胞，证实了CAR在膜上的稳定表达。这一突破为推进犬自体CAR-T 细胞治疗提供了关键的技术基础。
展开英文摘要原文
Lymphoma constitutes 24% of canine neoplastic diseases and 85% of haematopoietic tumours, with B-cell subtypes accounting for 60%-80% of cases. As the most prevalent spontaneous tumour in canines, this disease model holds significant translational value for human non-Hodgkin lymphoma research. To address diagnostic limitations in canine B-cell lymphoma, we developed a canine-specific CD19 monoclonal antibody (HAC19. 1) with high affinity and established a dual-platform detection system compatible with flow cytometry and immunohistochemistry.
Additionally, a novel CD19-targeting chimeric antigen receptor (CAR) gene sequence (HUA-1) was engineered and successfully transduced into Jurkat cells via lentiviral vectors, confirming stable CAR membrane expression. This breakthrough provides critical technical groundwork for advancing autologous CAR-T cell therapy in canines.
论文信息
- 作者
- Li H、Lu Q、Huang X、Li M、Zhou Y、Chen M、Qin M、Kang J
- 单位
- College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.China
- 期刊
- Veterinary and comparative oncology2026 Jun
- 原文标识
- PubMed 41847725 · DOI 10.1111/vco.70061